OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, a leader in the specialty pharmacy industry, is excited to announce the availability of Galderma's latest medication, NEMLUVIO® (nemolizumab-ilto), for the treatment of Prurigo Nodularis in adults. This partnership marks a significant advancement in the therapeutic options available to patients suffering from this chronic, debilitating skin condition.
Prurigo Nodularis, characterized by intensely itchy nodules of the skin, significantly impacts patients' quality of life. The introduction of Galderma's innovative therapy offers new hope for effective management and symptom relief.
"We are thrilled to offer our patients access to Galderma's cutting-edge medication for Prurigo Nodularis," said Kristin Williams, president of Amber Specialty Pharmacy. "This collaboration aligns with our commitment to providing the best possible care and improving the lives of those affected by rare and chronic conditions."
Amber Specialty Pharmacy will begin offering Galderma's new medication immediately, ensuring patients have timely access to this breakthrough therapy. For more information, please visit www.AmberPharmacy.com or contact Amber Specialty Pharmacy’s customer service team at (888) 370-1724.
# # #
About Amber Specialty Pharmacy
Amber Specialty Pharmacy is a pioneer in providing specialty pharmacy services and patient support. With a focus on rare and chronic conditions, Amber Specialty Pharmacy delivers comprehensive care and innovative solutions that enhance patient outcomes.
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. Galderma delivers an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
For more on FDA approval and indication information, visit https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo
Important Safety Information
Indication: NEMLUVIO®(nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis. Contraindication: Known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO. Warnings/Precautions: Hypersensitivity reactions have been reported with NEMLUVIO use. If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. Adverse Events: Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information including Patient Information.
